Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR9.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR2.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR1.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR4.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR3.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR5.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR8.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR7.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR6.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR22.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR23.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR13.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR24.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR17.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR11.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR19.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR15.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR27.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR14.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR25.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR16.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR26.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR10.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR18.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR20.htm
EX-10.1 - EXHIBIT 10.1 - HEALTH DISCOVERY CORPex10-1.htm
EX-32.1 - EXHIBIT 32.1 - HEALTH DISCOVERY CORPex32-1.htm
EX-10.2 - EXHIBIT 10.2 - HEALTH DISCOVERY CORPex10-2.htm
EX-31.1 - EXHIBIT 31.1 - HEALTH DISCOVERY CORPex31-1.htm
10-Q - FORM 10-Q - HEALTH DISCOVERY CORPt74989_10q.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR21.htm
v2.4.0.6
INVESTMENT IN AVAILABLE FOR SALE SECURITIES
9 Months Ended
Sep. 30, 2012
Investments, Debt and Equity Securities [Abstract]  
INVESTMENT IN AVAILABLE FOR SALE SECURITIES
Note G – INVESTMENT IN AVAILABLE FOR SALE SECURITIES
 
The Company has elected the fair value option in accordance with ASC 825, Financial Instruments, as it relates to its shares held in NeoGenomics’ common stock that were acquired resulting from the NeoGenomics Master License Agreement executed on January 6, 2012. Management made the election for the fair value option related to this investment because it believes the fair value option for the NeoGenomics common stock provides a better measurement from which to compare financial statements from reporting period to reporting period. No other financial assets or liabilities are fair valued using the fair value option.
 
The Company’s investment in NeoGenomics’ common stock is recorded on the accompanying balance sheets as of September 30, 2012 under the caption Investment in Available for Sale Securities. The carrying value of this investment on the date of acquisition approximated $1,945,000. The change in fair value from the acquisition date to September 30, 2012 is $1,502,580 and is classified as other income under the caption Unrealized Gain on Available for Sale Securitiesin the accompanying statements of operations. For the three months ended September 30, 2012, an unrealized gain of $1,135,380 was recognized in the statements of operations andan unrealized gain of $1,502,580 was recognized for the nine months ended September 30, 2012. The Company classifies its investment as an available for sale security presented as a trading security on the balance sheet and the fair value is considered a Level 1 investment in the fair value hierarchy. The September 30, 2012 fair value of the investment of $2,862,510 is based on the closing stock price of the NeoGenomics common stock at the end of the reporting period.
 
On August 13, 2012, the Company sold 409,000 shares of NeoGenomics and received proceedsin the amount of $922,711. This transaction resulted in the Company recognizing a Realized Gain on the Sale of Available for Sale Securities in the accompanying statements of operations in the amount of $337,841 in the current period.
 
As of September 30,2012 the Company holds 951,000 shares of NeoGenomics stock as compared to the initial 1,360,000 shares acquired as a result of the of the NeoGenomics Master License Agreement.